Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
説明 | PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials. |
ターゲット&IC50 | 3CLpro (SARS CoV-1):0.27 nM, 3CLpro (SARS CoV-2):4 nM |
分子量 | 472.53 |
分子式 | C24H32N4O6 |
CAS No. | 870153-29-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (529.07 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-00835231 870153-29-0 Microbiology/Virology SARS-CoV Inhibitor SARS coronavirus SARS CoV-2 COVID-19 SARS CoV-1 PF00835231 3CLpro inhibit PF 00835231 inhibitor